Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nothing is for sure with ADXS
if it were, we would be at $50 now.
However, I like the idea of $50 share
correct! with EMA approvel, $50.00 is for sure.
Thanks gold - nice timeline. My guess we are in stage 3.
I assume you mean now, Gold? Alot higher buyout if it were to come after EMA approval.
agree, minimum $30.00 pps if buyout would occur.
The difference between your examples and mine is that mine are realistic. With EMA approval we could easily see a buyout in the billions. If you don't believe that then I have no idea why you own the stock.
Lots of wishful thinking for a $5 stock with an unproven mgmt team and BOD that has yet to deliver a clear direction for the company. Well the lower the price goes the bigger the perceived value is right? Great job Sidransky, Appel and the rest of the BOD.
http://coviewcapital.com/ma-services/sell-side-advisory/
The Channel group partner, if Lombardo were hired to sell advaxis, that's how much time they need to process.
"Heck, if they were to shut off the manipulation machine and Lombardo raises non-dilutive cash, the market cap would quickly reach $1 billion+. Throw in EMA approval on top of that and the market cap would be $2-3 billion. It's all a matter of time frame and whether Lombardo raises cash the good way."
Heck, if a BP bought us tomorrow for $5 billion, we would quickly reach $5 billion. Heck, if AXAL showed it cured cancer we would reach $10 billion . Heck, if Lombardo sells HER2 tomorrow for $2 billion, there's another $2 billion bolted onto our market cap. Throw HOT in there and, you got it, another $2 billion to the $2 billion for HER2. Heck, if ADXS goes to $100 I'll retire.
I get the feeling that someone is waiting on something to move this down or up...
I would vote yes for $20, although sad to know with competent mgt it could have been $50, with great mgt, $100+
But right now we are behind and low on money...not good for a biotech
"Anyone still projecting a multi-billion valuation on ADXS - now a late stage biotech valued at only $200 million - needs to take a hard look at reality."
I'm still projecting a multi-billion valuation on ADXS, and I have taken a hard look at reality. EMA approval plus buyout = several billions. EMA approval plus strong interim Phase 3 data = billions. Heck, if they were to shut off the manipulation machine and Lombardo raises non-dilutive cash, the market cap would quickly reach $1 billion+. Throw in EMA approval on top of that and the market cap would be $2-3 billion. It's all a matter of time frame and whether Lombardo raises cash the good way.
I am all for buyout. $20 sounds dream to me.
I AM UP - I LOVE ADXS
ARE YOU A MKT TIMER TOO "FRAUD FIGHTWE??? LOL
Since proclaiming he is going to enhance shareholder value we are down over 40%.
Ira you make Sandman look like a genius!
I am up. I AM BULLISH ON ADXS
ARE YOU A MARKET TIMER??? LOL
Yep, kinda hard to produce evidence when hedge funds have bought legislation that affords them anonymity.
US market life time high & 10 year of bull market
and I am down almost 70 percent.
ADXS long shareholder are the worst investor in US Market.
We should all quit investing. LOL
Very true! Fortunately other kind folks on this board keep me updated with their great posts. This is truly a Great MB.
PETX either blew right past us....or we sunk way past them.
Either way, it's indespicably unfreakingbelievable.
Okay, good luck with that "evidence," or lack thereof. A complete fantasy. But you stick with it. The board of directors and Alan Greenspan are also part of the ADXS-Adage criminal conspiracy.
grown -
I believe researchers are well aware of the human applications for HER2 and the broader implications if it's successful treating canine osteosarcoma
And that is exactly what I believe Lombardo is betting on. Concentrate resources on AXAL and when PETX gets its approval....then HER2 will be put up for sale. Approval for canine, will increase the selling price. If AXAL gets EU approval, it my also make sense to sell the license agreement with PetX. Sell the future revenue stream from royalties along with HER2. The buyer and seller both win (and shareholders too).
"Apparently a lot of parties knew about a possible FDA hold before it happened." Really? Like who? Or is that "nothing more than a guess"?.
"Concluding that DOC fed Adage in particular inside information is nothing more than a guess. It amazes me how people just accuse various parties affiliated with ADXS to have committed crimes with no evidence." No it is not just a guess...we know this stock has been manipulated, and no one had a bigger position to benefit from manipulation than Adage. We also know they dumped shares big time after DOC got canned (with no explanation of his firing). You don't have to be Sherlock Holmes to wonder if there was something dirty going on with Adage.
Just because we arent the FBI doesn't mean it is unreasonable to draw conclusions based on the actions of Adage.
Apparently a lot of parties knew about a possible FDA hold before it happened. Concluding that DOC fed Adage in particular inside information is nothing more than a guess. It amazes me how people just accuse various parties affiliated with ADXS to have committed crimes with no evidence. Yet they state it as a foregone conclusion.
" about 80,000 beers ago"
Now THAT is time well spent. Plus probably the only way to keep one's sanity as an ADXS shareholder.
you were commenting on short as well as moles. And the behavior of Adage and the stock pre-hold and pos- DOC supports the theory that DOC had some deal with Adage to act like a mole.
I was quoting from another poster. I think the results were excellent.
Easy, I did not mean to imply the HER2 trial in canines did not do well, I was just quoting from a post. When I saw that it more than doubled OS, I was floored. Those are great results. My thought, like some others here, is Big Tony is pushing those constructs that are far along enough (and partially paid for) to get us to approval in a quicker fashion. Some have stated the longer it takes us to get to the promised land the quicker competition will overtake us. Advances are coming at an incredible rate now as opposed to just a short time ago and there will always be newer, better treatments coming up behind us (and everyone else. The beauty of Advaxis, I think, is it can be and will be used in combination with just about anything that is current or new. When the HER2 results from the human trials are released and assuming they are good, that could up the interest and value that licensing could bring.
I see PETX 30 cents today. Maybe we will hear something soon from them???
Mr. Lombardo release the deal or buyout or something.
Come on
Yes, hard to understand the USDA's delay
The PETX HER2 trial results were a virtual blockbuster. Many of the patients (lol) have survived for several years beyond the expected OS, if I understand it correctly.
The near term event that will impact the longer term future of HER2 is PETX gaining USDA approval to commercialize the construct for veterinary application. I know we're talking dogs vs human applications but the similarities and parallels of the target cancers are very strong.
The required PETX field trials of AT-014 were good or PETX could not or would not have proceeded with the USDA conditional approval request.
I believe researchers are well aware of the human applications for HER2 and the broader implications if it's successful treating canine osteosarcoma.
G.B.
Hovacre, I totally agree with you! My whole point was Dew Dilligence was the one implying that if our HER2 results were that good that Lombardo would continue to pursue HER2 at this time. I'm stating that we need to conserve cash and pursue our phase 3 trials to bring them to fruition. My whole point was calling out DEW on his remarks about our HER2 trials. He just stated that if they were that good we would still pursue them even if money is tight. Lombardo is doing the right things for us the shareholders in my opinion starting with slowing down ontrials that are too far out at this time. Then using what cash we have on getting AXAL to some kind of approval without diluting at such low prices. I'm not against dilution if it's done at much higher valuations than down here! Lombardo to me is being fiscally responsible with our cash and is doing everything possible to add value to ADXS' s share price! Patience is what's needed now he just came on board and needs a little time to turn the ship around in the right direction. Shorts we're hoping for major cash burns monthly like Dan had planned but now the board has put in a CEO to right the ship and steer us to be a revenue producing company inspite of the damage Dan had done by going full bore on every trial in our pipeline. Lombardo realizes that if he can get AXAL approved in the EU we will be off to the races!
They already have the safety data,it was the primary endpoint of the study,and it was good. They`re waiting on the secondary endpoint data,which was efficacy,and they should be getting it in a few months.
Have you heard or read anything about the safety profile of ADXS HER2 construct? I have read comments over the years that suggests it would be wildly effective, but could generate some side effects in humans, potentially dangerous for a certain small percentage of patients.
I bring this up as it relates to cost. Hypothetically if say 5% of the patients were at higher risk of life threatening complications, HER2 with legitimate life saving efficacy but side effects could still be approved (eventually) and be incredibly lucrative, but those trials and working with FDA thru the process could take some time and be very costly.
If that is true it would be logical to sell or license to a Big Pharma who could easily take on the heavy lifting and afford the cost.
Even if safety profile is no problem at all, it still makes sense to sell or license this out due to costs involved.
... and will probably be shopped around looking for a partner.
I have spoken with Noelle about the HER-2 human trial where it was being used for multiple HER-2 cancers. The human trial was ongoing. The company decided to stop pursuing HER-2 because the next step was a study in pediatric osteosarcoma which is a very small market. As much as the company would like to help those patients, it needs to conserve and prioritize the use of its resources. The efficacy data from the human HER-2 trial is being compiled and will be released at some point in the future.
Even if the HER2 canine trials went very well, it makes sense for ADXS to pursue the other indications for their LM platform first, especially those in phase 3. Furthermore, HER2-positive tumors have a lot of existing and upcoming competition.
Fantastic preclinical results still puts you at least 5 or 6 years out from a product. Likely longer. It should not be read as a strong indicator that the trial went poorly.
Isn't that a 3 to 4 step process? ADXS shaved off weeks of a multiple month long process. Such idiots, right? or maybe they are increasing efficiency/profit potential!
Any idea why the history of this trial shows "product_exported_from_us"?
Thanks Julius, that was about 80,000 beers ago so my memory is probably fading perhaps. Right before the clinical hold aye; was only one patient dosed or did the trial resurrect after the hold was lifted? Thanks
Interesting that this is about the time of the EU patent filing.
Hi Iggy, lots of talk; but never saw human dosing? Just my drunk backwoods take.
Now I'm confused. I thought there was an HER2 phase 1 running somewhere? If not, then what "data" did they look at, as per the pr about putting HER2 on hold?
Your exactly correct Huskercatman! Seems the canine trials are going great yet we have no human trials to date. Yet some people here would want you to believe our HER2 trials haven't been successful enough to warrant further trials? What? Lombardo is conserving cash at this time .. We're not abandoning our HER2 trials all together we're just not going to spend money starting a new trial! In fact we have fast track designation .
I guess our HER2 canine trials aren't good enough to pursue them in human trials? I thought our PETX trials were going super? Seems the dogs are surviving way past SOC treatments so why are we not good enough for pursuing HER2 in human trials?
spread the word. I did
Followers
|
396
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
108192
|
Created
|
12/05/05
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |